Long-term weight loss for patients with obesity proved mostly successful after taking prescription-only injectable ...

Nearly 4.4 million adult New Yorkers, or 30%, have obesity, but access to weight-loss medications varies based on a variety ...

One of the world’s largest drug manufacturers is suing a small east metro wellness center over the way it marketed and sold a ...

People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the ...

Four key factors can greatly impact how much weight people lose while taking GLP-1 drugs like Ozempic, Wegovy, Victoza, and ...

Injectable prescription drugs that reduce appetite — like Ozempic, Saxenda and Mounjaro — have skyrocketed in popularity in ...

Ozempic and its weight-loss cousin, Wegovy, outperform another longstanding weight-loss drug that targets the same ho ...

GLP-1 supplements are advertised as a cheaper alternative to weight loss with Ozempic or Wegovy. Doctors explain if they help ...

While GLP-1 medications like Ozempic and Wegovy hold promise for both weight loss and diabetes management, their potential for accidental misuse requires caution.

Ozempic maker Novo Nordisk’s highly anticipated new obesity pill, Amycretin, shows the potential for much greater and faster ...

Weight loss shots like Ozempic and Wegovy have been linked to 162 deaths in the United States over the past six years, according to a report.

Novo Nordisk presented data on its next-generation weight-loss candidate, amycretin, which showed a significant 13% weight ...